| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;101:1138.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Clinical Outcomes After Ablation and Pacing Therapy for Atrial Fibrillation
A Meta-Analysis
From Virginia Commonwealth University/Medical College of Virginia (M.A.W., K.A.E.); the University of Minnesota, Minneapolis (C.B.-M.); and the University of Alabama, Birmingham (G.N.K.).
Correspondence to Mark A. Wood, MD, Medical College of Virginia, PO Box 980053, Richmond, VA 23298-0053.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Radiofrequency ablation of the atrioventricular node and permanent pacing are used for symptomatic relief in patients with medically refractory atrial fibrillation. In this study, meta-analysis was used to clarify clinical outcomes and survival after ablation and pacing therapy using data from the published literature.
Methods and Results—We used 21 studies with a total of 1181 patients in the meta-analysis. All patients had medically refractory atrial tachyarrhythmias, primarily atrial fibrillation (97%). Nineteen measures of clinical outcome, encompassing quality of life, ventricular function, exercise duration, and healthcare use, were derived from the studies. The meta-analysis demonstrated significant improvement after ablation and pacing therapy in all outcome measures except fractional shortening, which demonstrated a trend toward improvement (P=0.08). Ejection fraction did show significant improvement (P<0.001). The calculated 1-year total and sudden death mortality rates after ablation and pacing therapy were 6.3% and 2.0%, respectively.
Conclusions—Ablation and pacing therapy improves a broad range of clinical outcomes for patients with medically refractory atrial fibrillation. The calculated 1-year mortality rates after this therapy are low and comparable with medical therapy.
Key Words: ablation • pacing • fibrillation • clinical trials • survival
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atrial fibrillation affects >2 million people in the United States alone.1 It is estimated that 12% of patients with atrial fibrillation are refractory to medical therapy.2 These patients may suffer intractable symptoms and a severely diminished quality of life.3 Radiofrequency catheter ablation of the atrioventricular (AV) node to produce complete heart block followed by permanent pacemaker implantation (ablation and pacing therapy) is a recognized treatment to alleviate symptoms in medically refractory patients.4 Data supporting the use of this procedure are derived from numerous, small, uncontrolled clinical trials, however. The clinical response after ablation and pacing therapy varies considerably.5 6 7 8 9 In addition, reports of sudden death after ablation and pacing have raised concerns regarding excessive mortality that is directly attributable to the procedure.10 The clinical evaluation of ablation and pacing therapy is complicated by the multiple, small, uncontrolled clinical studies; the use of differing instruments to measure outcomes; and the variable outcome results. Currently, very limited data have been derived from randomized, controlled studies to clarify these findings.5 11
When properly applied, meta-analysis can increase the statistical power of primary end points, clarify disagreement among studies, and estimate effect sizes to quantify outcomes from a collection of individual reports.12 13 14 15 16 17 18 The purpose of this study was to quantify the effects of ablation and pacing therapy on measures of clinical outcome and survival using meta-analysis.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Search Strategy
A literature search for all published outcome studies of radiofrequency ablation and pacing therapy was performed for the period from January 1989 through June 1998. The search strategy included the authors’ knowledge of the literature, a review of bibliographies of published reports, manual library searches, and computerized MEDLINE searches. Criteria for inclusion in the analyses were as follows: (1) peer-reviewed, full-length articles published in English, (2) the use of radiofrequency catheter ablation to produce complete heart block in the setting of medically refractory atrial tachyarrhythmia or explicit separation of radiofrequency ablation data from direct-current catheter ablation in comparative studies, and (3) numeric representation of measures of clinical outcome before and after ablation and pacing and/or explicit data on sudden death or total mortality presented with follow-up duration. Abstracts, studies using only direct-current ablation, and studies examining only AV nodal modification for ventricular rate slowing rather than complete AV junctional ablation were excluded from the meta-analysis. Because only 2 randomized trials were found during the search, their data were included in the analysis with the nonrandomized trials.5 11
Statistical Analysis
Results from 19 measures of clinical outcome were
extracted from the studies (Table 1
). These included measures
of exercise duration, symptoms, quality of life, cardiac function, and
healthcare use. The estimate of the effect size was defined as the mean
difference in a measure before and after radiofrequency ablation and
pacing. All measures reported on Likert-type scales were standardized
to proportions to be combined across studies. For each of the 19
measures, effect size and variance were calculated using the maximum
likelihood method (Fastpro software, Academic Press, Inc).
Estimates of the effect size and 95% confidence intervals (CIs) were
made by comparing measures before and after ablation within each study
and then combining these measures across studies using the
random-effects model.17
|
The survival analysis used a Kaplan-Meier model adjusted
for time to control for different follow-up durations among studies.
The combined 1-year mortality rates with 95% CIs were calculated by
the DerSimonian and Laird method.17 18 Because of
the broad distribution of follow-up durations (10 studies had durations
1 year and 11 studies had durations <1 year), 1-year mortality rates
were calculated from studies with 1 year of follow-up and monthly
mortality rates were calculated from studies with <1 year of
follow-up.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
On the basis of key search words, the search strategy produced >400 studies. A total of 21 studies containing a total of 1181 patients met the inclusion criteria. The patient characteristics for each study are summarized in Table 2
. The
outcome and survival findings from each study are summarized in Table 3. All studies included only patients
with highly symptomatic, medically refractory atrial
fibrillation (97%), atrial flutter,3 9 10 25 27 or atrial
tachycardia (3%).18 19 30 31
|
|
The outcomes analysis included 642 patients in 15 studies (median patients per study, 25; range, 10 to 156).1 The average duration of follow-up ranged from 48 days to 2.3 years. Thirteen studies were nonrandomized trials, and 2 compared ablation and pacing therapy with pharmacological therapy or radiofrequency modification of AV nodal conduction.5 11 Data on 1073 patients from 16 studies (median patients per study, 30; range, 11 to 235) was included in the mortality analysis.2 The average duration of follow-up ranged from 3 months to 2.3 years.
Clinical Outcomes
The effect sizes and 95% confidence intervals for each of the 19
outcome measures are illustrated in Figures 1 through 3 and
listed in Table 4. All measures showed
significant improvement except for fractional shortening, which showed
a trend toward improvement (P=0.08). Cardiac symptom scores,
quality-of-life measures, and healthcare use showed improvement in all
individual studies. Among individual studies, exercise duration and
ejection fraction were unchanged by ablation and pacing therapy in 4 of
7 and 5 of 11 studies, respectively (Table 3
). The
meta-analysis results showed significant improvement in both of
these measures. Fractional shortening was improved in 2 of 3
studies.9 28 29
|
|
0.001 for all
effect sizes except fractional shortening, which is
P=0.08 (Table 4
|
|
Mortality
The calculated monthly and 1-year total mortality rates were 1.4%
(95% CI, 0.04% to 2.4%) and 6.3% (95% CI, 5.5% to 7.2%),
respectively. The range of total mortality rates for studies with 1
year of follow-up was 0% to 23%; it was 0% to 18% for studies with
<1 year follow up.
The calculated monthly and 1-year sudden death rates were 0.7% (95%
CI, 0.01% to 1.2%) and 2.0% (95% CI, 1.5% to 2.6%), respectively.
The range of sudden death rates for studies with 1 year of follow-up
was 0% to 9% and, for studies with <1 year follow-up, 0% to
6%.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The major findings of this study are as follows: (1) in patients with refractory atrial tachyarrhythmia, ablation and pacing therapy significantly reduces cardiac symptoms and healthcare use while improving exercise duration, quality of life, and ejection fraction, and (2) the 1-year total and sudden death mortality rates after ablation and pacing therapy are estimated to be 6.3% and 2.0%, respectively.
The long-term management of atrial fibrillation is often unsatisfactory, despite the availability of numerous pharmacological and nonpharmacological therapies. The ability of ablation and pacing therapy to provide relief to the most highly symptomatic patients meets a large and growing challenge in clinical practice. In this study, the improvement in symptoms, quality of life, and healthcare use after ablation and pacing therapy was uniform across studies and highly significant for the combined data. The variable effects on exercise duration and ventricular function reported among individual studies may result from the small sample sizes and patient selection biases. The mechanism of improved exercise duration is probably related to the salutary effects of strict heart-rate control on ventricular systolic function, diastolic function, filling time, and cardiac output.24 32 33
The improved left ventricular ejection fraction noted in these studies is an important feature of this therapy. In studies stratifying patients by ejection fraction before therapy, mean left ventricular function improved significantly in those patients with baseline impairment, but it remained unchanged or decreased slightly in those with normal ventricular function.6 28 Improved ventricular function after ablation and pacing may be attributed to enhanced diastolic filling times, improved cardiac mechanics, the withdrawal of negative inotropic drugs, and the reversal of tachycardia-induced cardiomyopathy.34
The mortality rates in some reports have raised concerns about excess deaths that are directly attributable to ablation and pacing therapy.10 19 31 In addition to a risk of pacing-system failure, a specific risk for sudden death due to polymorphic ventricular tachycardia after ablation and pacing has been identified.10 35 This complication seems to be minimized by programming to high baseline pacing rates (80 to 90 bpm) for 1 to 2 months after ablation.10 Previous mortality estimates may have been influenced by the early experience with direct-current catheter ablation and before the recognition of the risk for polymorphic ventricular arrhythmias.10 36
Recent studies using high-rate pacing have reported no sudden deaths at up to 25 months of follow up.5 11 31 The populations undergoing ablation and pacing have a high prevalence of structural heart disease and heart failure, which are associated with an intrinsic risk of mortality. The total mortality and arrhythmic death rates in the 1330 patients with atrial fibrillation who were followed in the Stroke Prevention in Atrial Fibrillation Trial were 6.7% and 2.4%, respectively, at 1.3 years of follow up.37 This meta-analysis describes very comparable mortality rates that do not seem to be disproportionate for the characteristics of the study group. Reports of sudden death in the absence of structural heart disease mandate careful consideration of the risks of this procedure in each individual patient, however.10
Limitations
The limitations of meta-analysis are well
recognized.38 The design excluded studies with data
presented in noncombinable formats. Also excluded were studies
not published in English, including European trials. The results of
studies from the European literature, however, are consistent
with the findings of this meta-analysis.39 This
analysis includes primarily small, uncontrolled studies. The
potential for a placebo effect in patients undergoing invasive
procedures could not be assessed without control
groups.40
Clinical Implications
This study supports the use of ablation and pacing therapy to
benefit patients with highly symptomatic, medically
refractory atrial fibrillation. The results of 5 small, randomized
trials comparing ablation and pacing therapy with pharmacologic
management, AV nodal modification, or pacemaker implantation alone have
also demonstrated the superiority of ablation and pacing for
symptomatic relief.5 9 11 20 41 Thus, it may
be argued that further outcome studies, randomized or not, using this
most recalcitrant population are not warranted.42 Until
sinus rhythm can be maintained in these patients, ablation and pacing
therapy can serve as a valuable palliative therapy.
The greater question about ablation and pacing therapy now concerns its role in the much larger population of patients with less symptomatic atrial fibrillation. The benefits of pharmacological rate control compared with the maintenance of sinus rhythm are under evaluation in the Atrial Fibrillation Follow-up Investigation of Rhythm Management, which is studying a general population of patients with recent-onset atrial fibrillation.43 The potential benefits of ablation and pacing therapy in this population include absolute heart rate control, diminished drug burden, improved ventricular function, and freedom from drug side effects. In broadening the indications for ablation and pacing, many questions still exist regarding patient selection, appropriate level of symptoms, requisite number of pharmacological trials, cost effectiveness and, above all, risk of morbidity and mortality related to the therapy. The findings of this meta-analysis with effect sizes for clinical outcomes may facilitate the design of future trials to address these issues.
|
Acknowledgments |
|---|
This study was supported in part by Medtronic, Inc, Minneapolis, Minn.
|
Footnotes |
|---|
Dr. Brown-Mahoney received limited financial support from Medtronic, Inc, for the statistical analysis, and Drs. Ellenbogen and Wood are consultant speakers and clinical investigators for Medtronic, Inc. Medtronic, Inc partially supported this study.
1 References 3, 5–9, 11, 18, 21, 23–25, 28, 29, 31. 
2 References 5–7, 9–11, 18–21, 24–27, 30, 31.
Received April 13, 1999; revision received September 21, 1999; accepted October 8, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.[Medline] [Order article via Infotrieve]
2. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Am J Cardiol. 1991;68:335–341.[Medline] [Order article via Infotrieve]
3.
Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect
of radiofrequency catheter ablation on health-related quality of life
and activities of daily living in patients with recurrent
arrhythmias. Circulation. 1996;94:1585–1591.
4.
Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN,
Myerburg RJ, Nacerelli GV, Wyse DG. Management of patients with atrial
fibrillation. Circulation. 1996;93:1262–1277.
5.
Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso
G, Bongiorni G, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone
S. Assessment of atrioventricular junction ablation and
DDDR mode-switching pacemaker versus pharmacological treatment in
patients with severely symptomatic paroxysmal atrial
fibrillation. Circulation. 1997;96:2617–2624.
6. Kay GN, Ellenbogen KA, Giudici M, Redfield MM, Jenkins LS, Mianulli M, Wilkoff B, and the APT investigators. The ablate and pace trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol. 1998;2:121–135.[Medline] [Order article via Infotrieve]
7.
Buys EM, van Hemel NM, Kelder JC, Ascoop CAPL, van
Dessel PFHM, Bakema L, Kingma JHL. Exercise capacity after His bundle
ablation and rate response ventricular pacing for drug
refractory chronic atrial fibrillation. Heart. 1997;77:238–241.
8. Wong J, Vohra J, Chan W, Mond HG, Lichtenstein M, Kritharides L, Warren RJ. Assessment of left ventricular function after radiofrequency and direct current atrioventricular node ablation. Aust N Z J Med. 1996;26:82–88.[Medline] [Order article via Infotrieve]
9. Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 1994;74:242–246.[Medline] [Order article via Infotrieve]
10. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol. 1997;20:343–348.[Medline] [Order article via Infotrieve]
11.
Lee S-H, Chen S-A, Tai C-I, Chiang C-E, Wen Z-C, Cheng
J-J, Ding Y-A, Chang M-S. Comparison of quality of life and cardiac
performance after complete atrioventricular
junction ablation and atrioventricular junction
modification in patients with medically refractory atrial fibrillation.
J Am Coll Cardiol. 1998;31:637–644.
12.
Thacker SB. Meta-analysis: a quantitative
approach to research integration. JAMA. 1988;259:1685–1689.
13. Glass GV. Primary, secondary, and meta-analysis of research. Educ Res. 1976;5:3–8.
14. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med. 1987;316:450–455.[Abstract]
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.. 1986;7:177–188.[Medline] [Order article via Infotrieve]
16.
Cappelleri JC, Ioannidis JP, Schmid CH, Ferranti SD,
Chalmers AM, Lau J. Large trials versus meta-analysis of
smaller trials: how do their results compare? JAMA.. 1996;276:1332–1338.
17. Raudenbush SW. Effects model. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994:301–322.
18. Eddy DM, Hallesblad V, Shachter R. Meta-Analysis by the Confidence Profile Method. Boston: Academic Press, Inc; 1992.
19. Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, Hassam R, Koutsounis H. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pacing Clin Electrophysiol. 1993;16:1275–1284.[Medline] [Order article via Infotrieve]
20. Twidale N, McDonald T, Nave K, Seal A. Comparison of the effect of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol. 1998;21:641–651.[Medline] [Order article via Infotrieve]
21. Heinz G, Siostrzonek P, Kreiner G, Gössinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 1992;69:489–492.[Medline] [Order article via Infotrieve]
22. Natale A, Zimerman L, Tomassoni G, Kearney M, Kent V, Brandon MJ, Newby K. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol. 1996;78:1431–1433.[Medline] [Order article via Infotrieve]
23.
Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N,
Rosenqvist M. Prospective study of left ventricular
function after radiofrequency ablation of
atrioventricular junction in patients with atrial
fibrillation. Br Heart J. 1995;74:261–267.
24. Geelen P, Goethals M, De Bruyne B, Brugada P. A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction. Am J Cardiol. 1997;80:1606–1609.[Medline] [Order article via Infotrieve]
25. Fitzpatrick AP, Kourouyan HD, Siu A, Lee RJ, Lesch MD, Epstein LM, Griffin JC, Scheinman MM. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J. 1996;131:499–507.[Medline] [Order article via Infotrieve]
26. Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. Pacing Clin Electrophysiol. 1995;19:1609–1614.
27. Olgin JE, Scheinman MM. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol. 1993;21:557–564.[Abstract]
28.
Jackman WM, Wang X, Friday KJ, Fitzgerald DM, Roman C,
Moulton K, Margolis PD, Bowlman AJ, Kuck KH, Nacarelli GV, Pitha JV,
Dyer J, Lazzara R. Catheter ablation of
atrioventricular junction using radiofrequency current
in 17 patients. Circulation. 1991;83:1562–1576.
29. Darpo B, Walfridsson H, Aunes M, Bergfeldt L, Edvardsson N, Linde C, Lurje L, van der Linden M, Rosenqvist M. Incidence of sudden death after radiofrequency ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol. 1997;80:1174–1177.[Medline] [Order article via Infotrieve]
30. Morady F, Calkins H, Langberg JJ, Armstrong WF, De Buitleir M, El-Atassi R, Kalbfleisch SJ. A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction. J Am Coll Cardiol. 1993;21:102–109.[Abstract]
31. Jordaens L, Rubbens L, Vertongen P. Sudden death and long-term survival after ablation of the atrioventricular junction. Eur JCPE. 1993;3:232–237.
32. Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R, Harvey M, Strickberber SA, Man KC, Morady F. Effect of an irregular rhythm on cardiac output. Am J Cardiol. 1996;78:1433–1436.[Medline] [Order article via Infotrieve]
33. Herbert WH. Cardiac output and varying RR interval of atrial fibrillation. J Electrocardiol. 1973;6:131–135.[Medline] [Order article via Infotrieve]
34. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709–715.[Abstract]
35. Peters RH, Wever EF, Hauer RN, Wittkampf FH, de Medina R. Bradycardia dependent QT-prolongation and ventricular fibrillation following catheter ablation of the atrioventricular junction with radiofrequency energy. Pacing Clin Electrophysiol. 1994;17:108–112.[Medline] [Order article via Infotrieve]
36.
Evans GT, Scheinman MM, Bardy G, Borggrefe M, Brugada
P, Fisher J, Fontaine G, Huang SK, Josephson M. Predictors of
in-hospital mortality after DC catheter ablation of
atrioventricular junction: results of a prospective
international, multicenter study. Circulation. 1991;84:1924–1937.
37. Flacker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20:527–532.[Abstract]
38. Abrahamson JH. Meta-analysis: a reveiw of the pros and cons. Pub Health Rev. 1990;18:1–47.
39. Gjesdal K, Platou ES, Aass H, Orning OM. Ablasjon av His-bunten ved atriale arytmier: en utvei nar medikamentene ikke virker. Tidsskr Nor Laegeforen. 1996;116:3222–3225.[Medline] [Order article via Infotrieve]
40. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1999;83:903–907.[Medline] [Order article via Infotrieve]
41.
Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu
R, Bottoni N, Lolli G. Assessment of atrioventricular
junctional ablation and VVIR pacemaker versus pharmacologic treatment
in patients with heart failure and chronic atrial fibrillation.
Circulation. 1998;98:953–960.
42. Wyse DG. Be still my beating heart: the Ablate and Pace Study. J Interv Card Electrophysiol. 1998;2:137–138.[Medline] [Order article via Infotrieve]
43. The planning and steering committee of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. Am J Cardiol. 1997;29:1198–1202.This study used meta-analysis to examine 19 measures of clinical outcome, which encompassed quality of life, ventricular function, exercise duration, healthcare use, and survival; these measures were derived from 21 published reports on ablation and pacing therapy for refractory atrial fibrillation. Eighteen of the 19 measures of clinical outcome were significantly improved after ablation and pacing therapy. The calculated 1-year total mortality and sudden death rates were 6.3% and 2.0%, respectively. Ablation and pacing therapy improves a broad range of clinical outcomes for patients with refractory atrial fibrillation and is associated with lower 1-year mortality rates.
This article has been cited by other articles:
 |
|
 |
|
  T. De Potter, A. Berruezo, L. Mont, M. Matiello, D. Tamborero, C. Santibanez, B. Benito, N. Zamorano, and J. Brugada Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation Europace, October 31, 2009; (2009) eup309v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Forleo and C. Tondo Atrial fibrillation: cure or treat? Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 187 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382. [Full Text] [PDF]
|
|
|
|
 |
|
 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): 1977 - 2016. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Khan, P. Jais, J. Cummings, L. Di Biase, P. Sanders, D. O. Martin, J. Kautzner, S. Hao, S. Themistoclakis, R. Fanelli, et al. Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart Failure N. Engl. J. Med., October 23, 2008; 359(17): 1778 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Proclemer, G. Allocca, D. Gregori, C. Bonanno, R. Ometto, A. Fontanelli, R. Mantovan, M. Crosato, V. Calzolari, D. Pavoni, et al. Radiofrequency ablation of drug-refractory atrial fibrillation: an observational study comparing 'ablate and pace' with pulmonary vein isolation Europace, September 1, 2008; 10(9): 1085 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ferreira, P. Adragao, D. M. Cavaco, R. Candeias, F. B. Morgado, K. R. Santos, E. Santos, and J. A. Silva Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation Europace, July 1, 2008; 10(7): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Tan, M. Rienstra, A. C.P. Wiesfeld, B. A. Schoonderwoerd, H. H.F. Hobbel, and I. C. Van Gelder Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation Europace, April 1, 2008; 10(4): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Betts Atrioventricular junction ablation and pacemaker implant for atrial fibrillation: still a valid treatment in appropriately selected patients Europace, April 1, 2008; 10(4): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koebe and P. Kirchhof Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation Europace, April 1, 2008; 10(4): 433 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Marine Catheter Ablation Therapy for Supraventricular Arrhythmias JAMA, December 19, 2007; 298(23): 2768 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Padeletti, P. Pieragnoli, V. Jentzen, and A. Schuchert The comorbidity of atrial fibrillation and heart failure: a challenge for electrical therapies Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I81 - I86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm Management of atrial fibrillation in patients with heart failure Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Tops, M. J. Schalij, E. R. Holman, L. van Erven, E. E. van der Wall, and J. J. Bax Right Ventricular Pacing Can Induce Ventricular Dyssynchrony in Patients With Atrial Fibrillation After Atrioventricular Node Ablation J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1642 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Steinberg Desperately Seeking a Randomized Clinical Trial of Resynchronization Therapy for Patients With Heart Failure and Atrial Fibrillation J. Am. Coll. Cardiol., August 15, 2006; 48(4): 744 - 746. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y H Lip and A. Tello-Montoliu Management of atrial fibrillation. Heart, August 1, 2006; 92(8): 1177 - 1182. [Full Text] [PDF]
|
|
|
|
|
|
K. F. Kwaku Cell Therapy for Rate Control in Atrial Fibrillation: A New Approach to an Old Problem Circulation, May 30, 2006; 113(21): 2474 - 2476. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Bunch, S. Mahapatra, G. K. Bruce, S. B. Johnson, D. V. Miller, B. D. Horne, X.-L. Wang, H.-C. Lee, N. M. Caplice, and D. L. Packer Impact of Transforming Growth Factor-{beta}1 on Atrioventricular Node Conduction Modification by Injected Autologous Fibroblasts in the Canine Heart Circulation, May 30, 2006; 113(21): 2485 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Szili-Torok, M. Bountioukos, A. J.Q.M. Muskens, D. A.M.J. Theuns, D. Poldermans, J. R.T.C. Roelandt, and L. J. Jordaens The presence of contractile reserve has no predictive value for the evolution of left ventricular function following atrio-ventricular node ablation in patients with permanent atrial fibrillation Eur J Echocardiogr, October 1, 2005; 6(5): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Naccarelli Antiadrenergic Therapy in the Control of Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S33 - S43. [Abstract] [PDF]
|
|
|
|
|
|
R. H. Falk Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation Circulation, June 14, 2005; 111(23): 3141 - 3150. [Full Text] [PDF]
|
|
|
|
|
|
M. Brignole, M. Gammage, E. Puggioni, P. Alboni, A. Raviele, R. Sutton, P. Vardas, M.G. Bongiorni, L. Bergfeldt, C. Menozzi, et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation Eur. Heart J., April 1, 2005; 26(7): 712 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Satish, K.-H. Yeh, M.-S. Wen, and C.-C. Wang Cardiac resynchronisation therapy versus dual site right ventricular pacing in a patient with permanent pacemaker and congestive heart failure Europace, January 1, 2005; 7(4): 380 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-F. Hsu, P. Jais, P. Sanders, S. Garrigue, M. Hocini, F. Sacher, Y. Takahashi, M. Rotter, J.-L. Pasquie, C. Scavee, et al. Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure N. Engl. J. Med., December 2, 2004; 351(23): 2373 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dorian, I. Mangat, A. Pinter, and V. Korley The Burden of Atrial Fibrillation: Should We Abandon Antiarrhythmic Drug Therapy? Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 257 - 262. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Nattel Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy? Can. Med. Assoc. J., September 28, 2004; 171(7): 752 - 753. [Full Text] [PDF]
|
|
|
|
|
|
C. Butter, G. Winbeck, M. Schlegl, M. Seifert, A. Wagner, E. Wellnhofer, and E. Fleck Management of atrial fibrillation in cardiac resynchronization therapy: Clinical practice of CRT: how to improve the success rate Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D106 - D111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Auricchio Pacing the left ventricle: does underlying rhythm matter? J. Am. Coll. Cardiol., January 21, 2004; 43(2): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
V.ér. Valls-Bertault, M. Fatemi, M. Gilard, P. Y. Pennec, Y. Etienne, and J.-J. Blanc Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation Europace, January 1, 2004; 6(5): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamada, D. O. Martin, K. A. Mowrey, N. L. Greenberg, and D. W. Wallick Effects of coupled pacing on cardiac performance during acute atrial tachycardia and fibrillation: an old therapy revisited for a new reason Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2630 - H2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Queiroga, H J Marshall, M Clune, and M D Gammage Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation Heart, September 1, 2003; 89(9): 1035 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.C. Gronefeld and S.H. Hohnloser Quality of life in atrial fibrillation: an increasingly important issue Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H25 - H33. [Abstract] [PDF]
|
|
|
|
|
|
G. C. Gronefeld, J. Lilienthal, K.-H. Kuck, S. H. Hohnloser, and for the Pharmacological Intervention in Atrial Fib Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation: Results from a prospective randomized study Eur. Heart J., August 1, 2003; 24(15): 1430 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Weerasooriya, M. Davis, A. Powell, T. Szili-Torok, C. Shah, D. Whalley, L. Kanagaratnam, W. Heddle, J. Leitch, A. Perks, et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT) J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berkowitsch, T. Neumann, K. Kurzidim, C. Reiner, M. Kuniss, G. Siemon, J. Sperzel, and H. F. Pitschner Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence Europace, January 1, 2003; 5(4): 351 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Lee and S.-A. Chen How important is the assessment of quality of life after pulmonary vein isolation for paroxysmal atrial fibrillation? Europace, January 1, 2003; 5(4): 357 - 359. [Full Text] [PDF]
|
|
|
|
|
|
L. Jordaens Treatment of atrial fibrillation by catheter-based procedures Europace, January 1, 2003; 5(s1): S30 - S35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Atrial Fibrillation Follow-up Investigation of A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation N. Engl. J. Med., December 5, 2002; 347(23): 1825 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. DiMarco Selective Vagal Stimulation for Rate Control in Atrial Fibrillation Circulation, October 1, 2002; 106(14): 1746 - 1747. [Full Text] [PDF]
|
|
|
|
|
|
S. Zhuang, Y. Zhang, K. A. Mowrey, J. Li, T. Tabata, D. W. Wallick, Z. B. Popovic, R. A. Grimm, A. Natale, and T. N. Mazgalev Ventricular Rate Control by Selective Vagal Stimulation Is Superior to Rhythm Regularization by Atrioventricular Nodal Ablation and Pacing During Atrial Fibrillation Circulation, October 1, 2002; 106(14): 1853 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W.H. Fung, S. K.W. Chan, L. Y.C. Yeung, and J. E. Sanderson Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials Eur J Heart Fail, August 1, 2002; 4(4): 489 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ozcan, A. Jahangir, P. A. Friedman, D. L. Hayes, T. M. Munger, R. F. Rea, M. A. Lloyd, D. L. Packer, D. O. Hodge, B. J. Gersh, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation J. Am. Coll. Cardiol., July 3, 2002; 40(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brignole, C. Menozzi, M. Gasparini, M. G. Bongiorni, G.L. Botto, R. Ometto, P. Alboni, C. Bruna, A. Vincenti, and R. Verlato An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation Eur. Heart J., June 1, 2002; 23(11): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Management of the Older Person With Atrial Fibrillation J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M352 - 363. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Leon, J. M. Greenberg, N. Kanuru, C. M. Baker, F. V. Mera, A. L. Smith, J. J. Langberg, and D. B. DeLurgio Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: Effect of upgrading to biventricular pacing after chronic right ventricular pacing J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1258 - 1263. [Full Text] [PDF]
|
|
|
|
|
|
T. Szili-Torok, G. P. Kimman, D. Theuns, D. Poldermans, J. R. T. C. Roelandt, and L. J. Jordaens Deterioration of left ventricular function following atrio-ventricular node ablation and right ventricular apical pacing in patients with permanent atrial fibrillation Europace, January 1, 2002; 4(1): 61 - 65. [Full Text] [PDF]
|
|
|
|
|
|
L. Jordaens and T. Szili-Torok Between Scylla and Charybdis: a choice between equally dreadful alternatives Europace, January 1, 2002; 4(3): 215 - 218. [PDF]
|
|
|
|
 |
|
 G.Y.H. Lip and F.L. L. S. Hee Paroxysmal atrial fibrillation QJM, December 1, 2001; 94(12): 665 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology Circulation, October 23, 2001; 104(17): 2118 - 2150. [Full Text] [PDF]
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Scheinman and F. Morady Nonpharmacological Approaches to Atrial Fibrillation Circulation, April 24, 2001; 103(16): 2120 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Falk Atrial Fibrillation N. Engl. J. Med., April 5, 2001; 344(14): 1067 - 1078. [Full Text] [PDF]
|
|
|
|
 |
|
 N. R Grubb and S. Furniss Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation BMJ, March 31, 2001; 322(7289): 777 - 780. [Full Text]
|
|
|
|
|
|
L. Jordaens How to make sure complications are avoided after an otherwise safe procedure Europace, January 1, 2000; 2(3): 191 - 192. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||